Why the study?
Does moderate-intensity oral anticoagulation alone or combined with low-dose aspirin prevent recurrent ischemic events in patients with non-ST-elevation acute coronary syndromes and previous CABG compared to low-dose aspirin alone?
Does moderate-intensity oral anticoagulation alone or combined with low-dose aspirin prevent recurrent ischemic events in patients with non-ST-elevation acute coronary syndromes and previous CABG compared to low-dose aspirin alone?
In patients with NSTE-ACS and prior CABG, moderate-intensity oral anticoagulation (alone or with aspirin) offers no superior protection against recurrent ischemic events compared to low-dose aspirin alone.
No role for moderate-intensity OAC in NSTE-ACS with prior CABG; confirms aspirin monotherapy for ischemic prevention.
Moderate-intensity oral anticoagulation alone or combined with low-dose aspirin does not appear to be superior to low-dose aspirin in the prevention of recurrent ischemic events in patients with non-ST-elevation acute coronary syndromes and previous CABG.
No takes yet. Share an insight, caveat, or question.
Huynh et al. (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: